Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.

Br J CancerJun 23, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Jiajia Yuan, Jifang Gong, Zhi Peng et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase 2, single-arm trial evaluated the efficacy and safety of infigratinib in 21 patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification. The study found a confirmed objective response rate of 23.8% and a median overall survival of 6.7 months, indicating preliminary antitumor activity in this population.

Key findings

  • Confirmed objective response rate of 23.8% (95% CI, 8.2-47.2).
  • Median progression-free survival was 3.4 months.
  • Median overall survival was 6.7 months.
  • Most common grade 3-4 adverse events included elevated aspartate aminotransferase and neutropenia.

Why it matters

The study highlights the potential of FGFR2 as a therapeutic target in advanced gastric cancer, suggesting that infigratinib may offer a new treatment option for patients with limited alternatives after multiple lines of therapy.

Source

PubMed · PMID 42337043Free full text on PubMed Central

Published in Br J Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchPreventive Medicine / Public Health

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

This systematic review and practice guideline, developed by a multidisciplinary panel using NUTRIGRADE, assessed Mediterranean diet evidence across nine health domains and one economic domain.

Nutr RevNov 12, 2026Read summary
Clinical ResearchOrthopedic Surgery

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

This multicenter randomized comparative-effectiveness noninferiority trial compared 30 days of aspirin, warfarin, or rivaroxaban for VTE prophylaxis after elective total hip or knee arthroplasty.

N Engl J MedNov 12, 2026Read summary
Clinical ResearchAnesthesiology

Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial.

This multicentre, randomised, double blind, placebo controlled trial assessed whether withholding ACE inhibitors or ARBs on the morning of surgery reduces perioperative hypotension in older adults undergoing non-cardiac…

BMJNov 11, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.